This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Feb;18(2):78-79.

doi: 10.1038/nri.2017.220. Epub 2017 Dec 27.

Immunotherapy: HLA genotype: good to be different

PMID: 29279611
DOI: 10.1038/nri.2017.220

Comment

Immunotherapy: HLA genotype: good to be different

Kirsty Minton. Nat Rev Immunol. 2018 Feb.

. 2018 Feb;18(2):78-79.

doi: 10.1038/nri.2017.220. Epub 2017 Dec 27.

Author

PMID: 29279611
DOI: 10.1038/nri.2017.220

No abstract available

PubMed Disclaimer

Comment on

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA. Chowell D, et al. Science. 2018 Feb 2;359(6375):582-587. doi: 10.1126/science.aao4572. Epub 2017 Dec 7. Science. 2018. PMID: 29217585 Free PMC article.

References

1. Science. 2017 Dec 7;:null - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program